TFSA Investors: 1 Little-Known Pot Stock Can Turn $6,000 Into $50,000

Here’s why growth investors should look to add Rubicon Organics to their TFSA portfolio right now.

potted green plant grows up in arrow shape

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The Tax-Free Savings Account (TFSA) is a registered account where Canadians can hold several investments including equities. As any withdrawals from the TFSA are exempt from Canada Revenue Agency taxes, it makes sense to allocate growth stocks to this account.

In 2021, Canadians can contribute a maximum of $6,000 to their TFSA. With the prospect of marijuana legalization south of the border driving the recent rally in the cannabis sector, it makes sense to buy and hold pot stocks in your TFSA that have secular tailwinds and multiple revenue drivers.

Here we take a look at one such Canada-based marijuana stock that can increase your wealth at an exponential rate.

Rubicon Organics is a top stock for your TFSA

Currently valued at a market cap of $151.6 million, Rubicon Organics is a small-cap pot stock that is flying under the radar. The company is a licensed producer of super-premium cannabis products. Rubicon claims to have developed a portfolio of brands that cater to consumer needs.

It owns and operates a 125,000 square-foot greenhouse facility in British Columbia. In May 2020, Rubicon received its medical license from Health Canada, allowing for direct-to-patient sales. On May 8 last year, it received a license to sell cannabis products for recreational use.

Rubicon has supply agreements with multiple provinces including British Columbia, Ontario, and Alberta. It also has a distribution agreement with Agro-Greens Naturals to sell its products in Saskatchewan and Manitoba.

In the third quarter of 2020, Rubicon reported net sales of $3.16 million, indicating a sequential growth of 219%. It reported a gross loss of $674,688 and an operating loss of $3.61 million. Its net loss from continuing operations for Q3 stood at $4.27 million or $0.09 per share.

In Q3, the company sold its Washington greenhouse for proceeds of $12 million while it also completed a non-brokered private placement for gross proceeds of $13.5 million. This allowed the company to end the September quarter with a cash balance of $8 million.

The bull case for the pot stock

Rubicon Organics claims to be a market leader in the premium cannabis space in Canada. The company has forecast demand for premium marijuana products to grow at a fast clip in the upcoming decade. The premium products segment accounted for 11% of the total Canadian pot market at the end of Q1 of 2020. This figure rose to 16% by the end of 2020.

Rubicon has forecast premium products to account for 26% of the total cannabis market in Canada by 2024, giving the company a total addressable market of $2.1 billion. Even if Rubicon can capture and maintain a 10% market share in the premium cannabis segment, it will generate annual sales of $210 million by 2024.

Analysts covering the stock expect 2020 sales to touch $11 million and rise by 365% to $51 million in 2021. Due to its premium products, Rubicon is poised to generate an adjusted net income of $0.12 per share in 2021. This is commendable given several Canadian marijuana producers are grappling with negative profit margins and high cash burn.

Rubicon stock is trading at a forward price to 2021 sales multiple of just 3 and a price to earnings multiple of 26 which is very reasonable given its stellar growth rates. Cannabis investors with a high-risk appetite can look to add Rubicon to their TFSA as it has the potential to gain 10x in the next few years.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »